J. Pharm. Pharm. Sci Journal of Pharmacy & Pharmaceutical Sciences J. Pharm. Pharm. Sci 1482-1826 Frontiers Media S.A. 12042 10.3389/jpps.2023.12042 Science archive Correction Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs Hashemzadeh et al. 10.3389/jpps.2023.12042 Hashemzadeh Nastaran 1 2 Rahimpour Elaheh 1 3 Jouyban Abolghasem 1 4 * 1 Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran 2 Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran 3 Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 4 Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Edited by: Fakhreddin Jamali, Alberta Innovates–Health Solutions, Canada

 *Correspondence: Abolghasem Jouyban, ajouyban@hotmail.com, jouyban@tbzmed.ac.ir 18 12 2023 2023 26 12042 13 09 2023 30 11 2023 Copyright © 2023 Hashemzadeh, Rahimpour and Jouyban. 2023 Hashemzadeh, Rahimpour and Jouyban

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs by Hashemzadeh N, Rahimpour E and Jouyban A (2022). J Pharm Pharm Sci. 25:391–401. doi: 10.18433/jpps33121 exhaled breath condensate bioequivalence pharmacodynamic pharmacokinetic inhalers

In the original article, there was a mistake in Table 1 as published. The order of the titles of the 2nd and 3rd columns have been reversed. The corrected form is that the title of the 2nd column is read as “EBC Conc.”, and that of the 3rd column as “Plasma Conc.”. The corrected column titles are marked with red font in the following Table.

An overview of drug concentrations in EBC and plasma samples, along with some details of the determination procedures.

Drug EBC Conc. Plasma Conc. Analytical platform for EBC samples LR1/LOD2 for EBC samples Significant feature References
Alprazolam NR3 0.005–0.02 ppm LC4–MS5 2–18/1 pg. filter1 Sensitive (30, 40)
Amikacin (0.42–0.68) × 10−3 ppm 1.91–2.81 ppm HPLC6–MS/MS 0.21–3,000/0.06 × 10−3 ppm Quick and efficient (43)
Amphetamine NR3 0.02–0.15 ppm LC–MS 2–18/3 pg. filter1 Sensitive (30, 40)
Aspirin 23.2–24.9 ppm 150–300 ppm Colorimetry 10–250/4.1 ppm High reliability (41, 42)
Benzoylecgonine NR3 0.018–0.14 ppm LC–MS 2–18/0.5 pg. filter−1 Sensitive (30, 40)
Buprenorphine NR3 0.001–0.005 ppm LC-MS/MS NR3/2.5 × 10−3 ppm Non-invasive and useful (14, 40)
Buprenorphine NR3 0.001–0.005 ppm LC–MS 2–18/2 pg. filter−1 Sensitive (30, 40)
Carbamazepine 0.3–0.5 ppm 2–12 ppm Spectroflourimetry 0.2–20/0.08 ppm Sensitive (15, 40
Cocaine NR3 0.1–0.3 ppm LC–MS 2–18/2 pg. filter−1 Sensitive (30, 40)
Codeine NR3 0.025–0.25 ppm LC-MS/MS NR3/0.1 × 10−3 ppm Non-invasive and useful (14, 40)
Daclatasvir 0.048–0.992 ppm 0.052–0.852 ppm Plasmon resonance 0.01–1.0/0.008 ppm Low LOD, low cost, sensitive (44, 45)
Daclatasvir NR3 0.052–0.852 ppm Spectroflourimetry 0.5–15 × 10−3/0.12 × 10−3 ppm Simple, fast and sensitive (46, 45)
Deferiprone 0.06–0.17 ppm 5–25 ppm Spectroflourimetry 0.06–1.50/0.06 ppm Simple, low EBC volume (21, 47)
Diazepam NR3 0.2–2 ppm LC–MS 2–18/1 pg. filter−1 Sensitive (30, 40)
Doxorubicin (48.9–203) × 10−3 ppm 0.006–0.09 ppm Spectrophotometric 0.02–0.2/0.00416 ppm Simple, sensitive and reliable (24, 40)
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine NR3 NR3 LC-MS/MS NR3/0.01 × 10−3 ppm Non-invasive and useful (14, 40)
Fentanyl NR3 0.005–0.3 ppm LC-MS/MS NR3/0.05 × 10−3 ppm Non-invasive and useful (14, 40)
Hydromorphone NR3 0.001–0.03 ppm LC-MS/MS NR3/1 × 10−3 ppm Non-invasive and useful (14, 40)
Hydrocodone NR3 0.01–0.1 ppm LC-MS/MS NR3/0.5 × 10−3 ppm Non-invasive and useful (14, 40)
Lamotrigine 0.592–0.771 ppm 3–15 ppm Spectrophotometric NR3/0.005 ppm Quick visual detection (28, 40)
Lamotrigine 0.55–1.19 ppm 3–15 ppm Spectroflourimetry 0.05–2.0/0.011 ppm Sensitive and fast (48, 40)
Meperidine NR3 0.1–0.8 ppm LC-MS/MS NR3/0.05 × 10−3 ppm Non-invasive and useful (14, 40)
Meropenem Not detectable 25.5 ppm UHPLCHR-MS 21,168 pg. filter−1/NR3 Non-invasive (55, 56)
Methadone NR3 0.05–0.5 ppm LC-MS/MS NR3/0.5 × 10−3 ppm Non-invasive and useful (14, 40)
Methadone 0.16–1.06 ppm 0.05–0.5 ppm Capillary electrophoresis 0.15–5 ppm/0.15 ppm Simple, sensitive and accurate (16, 40)
Methadone 23.6–275 pg.min−1 0.05–0.5 ppm LC–MS–MS 100–2000/3 pg/sample Feasible (12, 40)
Methadone (0.34–1.31) × 10−3 ppm 0.05–0.5 ppm LC 0.5–10 × 10−3/0.5 × 10−3 ppm Simple and low cost (23, 40)
Methadone 0.7–0.48 ppm 0.05–0.5 ppm Capillary electrophoresis 0.3–5/0.3 ppm Simple and fast (26, 40)
Methadone NR3 0.05–0.5 ppm LC–MS 2–18/0.5 pg. filter−1 Sensitive (30, 40)
Methamphetamine NR3 0.01–0.05 ppm LC–MS 2–18/1 pg. filter−1 Sensitive (30, 40)
Methotrexate (45.4–140.8) × 10−3 ppm 2.27 ppm Spectrofluorimetry 20–998.8 × 10−3/15.9 × 10−3 ppm Simple, fast and accurate (40, 49)
Metoprolol NR3 0.02–0.5 ppm Spectrofluorimetry 5−100 × 10−3/2.1–3.4 × 10−3 ppm Simple, low-cost (40, 50)
6-Acetyl morphine NR3 0.015–0.10 ppm LC–MS 2–18/1 pg. filter−1 Sensitive (30, 40)
Morphine NR3 0.01–0.15 ppm LC–MS 2–18/1 pg. filter−1 Sensitive (30, 40)
Morphine (0.10–5.48) × 10−3 ppm 0.01–0.15 ppm LC-MS/MS NR3/0.1 × 10−3 ppm Non-invasive and useful (14, 40)
Morphine (89–173) × 10−3 ppm 0.01–0.15 ppm GC7-MS NR3/2.1 × 10−3 ppm Repeatable and stable (20, 40)
Naloxone NR3 0.01–0.03 ppm LC-MS/MS NR3/0.25 × 10−3 ppm Non-invasive and useful (14, 40)
Naltrexone NR3 0.005–0.03 ppm LC-MS/MS NR3/0.5 × 10−3 ppm Non-invasive and useful (14, 40)
Oxazepam NR3 0.2–1.5 ppm LC–MS 2–18/1 pg. filter−1 Sensitive (30, 40)
Oxycodone NR3 0.02–0.05 ppm LC-MS/MS NR3/0.25 × 10−3 ppm Non-invasive and useful (14, 40)
Oxymorphone NR3 NR3 LC-MS/MS NR3/0.75 × 10−3 ppm Non-invasive and useful (14, 40)
Oxymorphone (29–82) × 10−3 ppm NR3 GC-MS NR3/1.5 × 10−3 ppm Repeatable, and stable (20, 40)
Paracetamol 1.12–4.68 ppm 2.5–25 ppm Colorimetry 0.2–10.0/0.49 ppm Specific and simple (17, 40)
Phenobarbital 0.21–1.65 ppm 1–5 ppm Spectrofluorimetry 0.1–10.0/0.024 ppm Feasible, efficient and simple (40, 51)
Phenobarbital 0.72–1.80 ppm 1–5 ppm Spectrofluorimetry 0.01–8.0/0.006 ppm Reliable and sensitive (40, 52)
Phenytoin 0.013–0.13 ppm 5–20 ppm Capillary electrophoresis 0.001–0.10/0.001 ppm Selectivity (40, 53)
Piperacillin 90 × 10−3 ppm 5–20 ppm Microfluidic sensor NR3/56 × 10−3 ppm Versatile and low LOD (39, 40, 54)
Piperacillin 45 pg 5–20 ppm UHPLCHR8-MS 988–203,895/3,083 pg.filter−1 Non-invasive (55, 56)
Propranolol 0.030 ppm 0.02–0.3 ppm LC-MS/MS 5.6–224 × 10−3 ppm/NR3 Simple, cheap and feasible (31, 40)
Tazobactam 90 × 10−3 ppm 7.7–13.7 ppm Microfluidic sensor NR3/56 × 10−3 ppm Versatile and low LOD (39, 40, 54)
Tazobactam 45 pg 7.7–13.7 ppm UHPLCHR8-MS 988–203,895/3,083 pg. filter−1 Non-invasive (55, 56)
Tetrahydrocannabinol NR3 0.001–0.007 ppm LC–MS 2–18/3 pg. filter1 Sensitive (30, 40)
Tobramycin (13.7–32.2) × 10−3 ppm 5–10 ppm Colorimetry 1.0–50.0 × 10−3/0.5 × 10−3 ppm Repeatable and low LOD (18, 40)
Tobramycin (21.4–41.6) × 10−3 ppm 5–10 ppm UV spectroscopy 1.0–50.0 × 10−3/(0.5 × 10−3 ppm Sensitive (13, 40)
Tobramycin (2.4–17.0) × 10−6 ppm 5–10 ppm LC–MS NR3 Wide LR (32, 40)
Tramadol HCl NR3 0.1–1 ppm LC-MS/MS NR3/0.5 × 10−3 ppm Non-invasive and useful (14, 40)
Salbutamol (32.2–645.0) × 10−6 ppm <0.01–0.02 ppm LC–MS NR3 Wide LR (32, 40)
Salbutamol sulfate (89–173) × 10−3 ppm <0.01–0.02 ppm GC-MS 0.615–5/370 ppm Wide LR and low LOD (40, 57)
Valproic acid (0.13–500) × 10−3 ppm 40–100 ppm GC-MS 1.0–5.0 × 10−3/0.08 × 10−3 ppm Repeatable, wide LR (27, 40)
Vancomycin 0.36–1.87 ppm 5–40 ppm Spectrofluorimetry 0.1–8/0.06 ppm Sensitive and low cost (19, 40)
Verapamil 0.059–0.067 ppm 0.05–0.25 ppm Spectrofluorimetry 0.02–12.0/0.008 ppm Suitable and accurate (29, 40)

LR1: Linear range; LOD2: Limit of detection; NR3: Not reported; LC4: Liquid chromatography; MS5: Mass spectrometry; HPLC6: High-performance liquid chromatography; GC7: Gas chromatography; UHPLCHR8: Ultra-high-pressure liquid chromatography high-resolution mass spectrometry.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.